Class: Tricyclics and Other Norepinephrine-reuptake Inhibitors
- TCAs
VA Class: CN601
Chemical Name: 1-Propamine, 3-dibenz[b,e]oxepin-11(6H)ylidene-N,N-dimethyl-, hydrochloride
Molecular Formula: C19H21NO HCL
CAS Number: 1229-29-4
Brands: SINEquan
Warning
- Suicidality
Antidepressants may increase risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18–24 years of age) with major depressive disorder and other psychiatric disorders; balance this risk with clinical need. Doxepin is not approved for use in pediatric patients <12 years of age. (See Pediatric Use under Cautions.)
In pooled data analyses, risk of suicidality was not increased in adults >24 years of age and apparently was reduced in adults ≥65 years of age with antidepressant therapy compared with placebo.
Depression and certain other psychiatric disorders are themselves associated with an increased risk of suicide.
Appropriately monitor and closely observe all patients who are started on doxepin therapy for clinical worsening, suicidality, or unusual changes in behavior; involve family members and/or caregivers in this process. (See Worsening of Depression and Suicidality Risk and Pediatric Use under Cautions.)
Introduction
Dibenzoxepin-derivative tricyclic antidepressant (TCA).
Uses for Doxepin (Systemic)
Depressive and Anxiety Disorders
Treatment of depression and/or anxiety in psychoneurotic patients. Psychoneurosis symptoms that respond well to doxepin include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension, and worry.
Treatment of depression and/or anxiety associated with alcoholism. (See Specific Drugs under Interactions.)
Treatment of depression and/or anxiety .
